Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Trial of amifostine in autologous stem cell transplant

Bone Marrow Transplantation volume 37, pages 117–118 (2006)Cite this article

We read with interest the recent publication of a prospective randomized trial of amifostine cytoprotection in myeloma patients receiving high-dose melphalan by the Australian Leukemia and Lymphoma Group.1 A few other studies have also shown similar cytoprotective benefit.2, 3, 4

However, our limited nonrandomized, retrospective experience suggests lack of beneficial effect of amifostine in autologous stem cell transplantation (ASCT).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Spencer A, Horvath N, Gibson J, Prince HM, Hermann R, Bashford J et al. Prospective randomized trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphelan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.

    Article  CAS  Google Scholar 

  2. Thieblemont C, Dumontet C, Saad H, Roche N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high dose melphelan conditioning and autologous peripheral blood progenitor cell transplantation in patients with multiple myeloma. Bone Marrow transplant 2002; 30: 769–775.

    Article  CAS  Google Scholar 

  3. Philips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphelan: a phase 1 study. Biol Blood Marrow Transplant 2004; 10: 473–483.

    Article  Google Scholar 

  4. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M et al. Amifostine can reduce mucosal damage after high-dose melphelan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Hematol 2000; 110: 300–307.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

    P Sastry, R Bhagwat, G Biswas, A Khadwal, P Narayanan, A Bakshi & P Parikh

Authors
  1. P Sastry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Bhagwat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Biswas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Khadwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Narayanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Bakshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sastry, P., Bhagwat, R., Biswas, G. et al. Trial of amifostine in autologous stem cell transplant. Bone Marrow Transplant 37, 117–118 (2006). https://doi.org/10.1038/sj.bmt.1705204

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705204

Search

Advanced search

Quick links